Perrigo Company plc (PRGO) is scheduled to report first-quarter 2024 results on May 7, before the opening bell. In the last reported quarter, the company posted an earnings surprise of 3.61%.Let’s see how things have shaped up for this announcement.Factors at PlayThe Zacks Consensus Estimate for Perrigo’s total revenues is pegged at around $1.1 billion, while the same for earnings stands at 24 cents per share. Both metrics indicate a decline from the year-ago quarter’s levels.Perrigo reports its results und ...

Proposed Divestment of Branded Prescription Pharma Business Further Supports Perrigo's Strategic Focus on Consumer Self-Care Total Purchase Consideration of up to €275 Million, Consisting of €190 Million in Cash Upfront and up to €85 Million in Potential Earnouts; Based on 2023 Adjusted EBITDA of ~€20M, Total Consideration Would be Accretive to Perrigo's Current Enterprise Value-to-EBITDA Multiple Expected Net Proceeds to be Redeployed for Debt Repayment Expected Impact From this Proposed Divestment was In ...

DUBLIN, April 23, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it plans to issue its first quarter 2024 financial results on Tuesday, May 7th, 2024, and host a conference call beginning at 8:30 A.M. (EDT).The earnings conference call will be available live via webcast to interested parties in the investor relations section of the Perrigo website at http://perrigo.investorroom.com/events-webcasts or by phone at 888-664-6383, In ...

Perrigo Has Opportunity to Leverage its Assets for More Profitable Future Paper Boat Creative/DigitalVision via Getty Images Perrigo (NYSE:PRGO) has increased dividends for 20 consecutive years, and I believe the initiatives outlined by the new CEO will propel Perrigo to Dividend Champion status and beyond. There are five potential catalysts forthcoming in 2024 that could support a share price increase. When combined with a depressed share price that is a result of a tumultuous decade, the shares seem to ha ...

Opill®, the first ever daily birth control pill available without a prescription in the United States, will be available in-store and online at retailers nationwide in the coming weeks and for pre-order from select retailers beginning this week   To maximize the impact and accessibility of Opill®, Perrigo has sought to ensure both the affordability and availability of Opill® on shelves across the country and online DUBLIN and GRAND RAPIDS, Mich., March 4, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRG ...

DUBLIN, Feb. 29, 2024 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that President and CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra are scheduled to present at the UBS Global Consumer and Retail Conference in New York City on Wednesday, March 13th at 4:00 PM EST.  Interested parties can access the webcast on the Perrigo website at http://perrigo.investorroom.com/events-webcasts. About Perrigo  Perrigo Company plc (NYSE: PRGO) is a ...

Perrigo Company plc (PRGO) reported adjusted earnings of 86 cents per share in the fourth quarter of 2023, beating the Zacks Consensus Estimate of 83 cents. Earnings were up 14.7% year over year. The upside can be attributed to lower operating expenses incurred by the company during the quarter.Net sales increased 0.1% year over year to $1.16 billion, missing the Zacks Consensus Estimate of $1.19 billion. The upside was driven by growth stemming from the acquisition of the U.S. & Canadian Good Start infant ...

Financial Data and Key Metrics Changes - Net sales in fiscal 2023 grew nearly 5%, driven by international and core US OTC businesses, with organic net sales increasing 2% [7][29] - Gross margin expanded 260 basis points to 38.8%, and operating margin expanded 130 basis points to 12.3% for the full year [7][30] - Full-year EPS was $2.58, an increase of 25% compared to the prior year, with strong cash flow conversion of 115% [7][31] Business Line Data and Key Metrics Changes - Significant growth was realized in skincare, nutrition, and women's health categories, partially fueled by HRA and Gateway acquisitions [8] - Healthy Lifestyle contributed strong growth, particularly in US smoking cessation products, while cough cold sales in the US grew mid-single digits [8][9] - The infant formula business faced challenges due to evolving regulatory guidelines, impacting overall performance [6][11] Market Data and Key Metrics Changes - Store brand dollar share of US OTC increased by 70 basis points, indicating a shift towards value offerings among consumers [9] - The US OTC business is performing well amid a normalizing consumer environment, with store brands gaining market share from national brands [5][6] Company Strategy and Development Direction - The company is focused on augmenting and strengthening its infant formula business while executing Project Energize to enhance operational efficiency [10][15] - The launch of Opill is seen as a key pillar for growth in women's healthcare, with plans for a comprehensive marketing strategy [20][23] - The company aims to centralize capital allocation decisions and streamline operations to enhance decision-making and simplify commercial operations [22][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in stabilizing the infant formula business despite current challenges, with expectations for recovery in the second half of 2024 [14][22] - The company anticipates mid-teens EPS growth in 2024, excluding the impact of the infant formula business, which is expected to be flat compared to 2023 [21][33] - Management emphasized the importance of executing remediation plans and enhancing brand-building capabilities to drive future growth [39][41] Other Important Information - The company reported a GAAP net loss of $4 million for 2023, with adjusted net income of $352 million [27] - Cash on the balance sheet increased to $751 million, with expectations for healthy cash flow conversion in 2024 [34][35] - The company plans to pay down $400 million in debt and increase capital investments in the infant formula business [35][36] Q&A Session Summary Question: Expectations for infant formula top line recovery - Management expects the first quarter to be the worst for infant formula, with gradual improvement anticipated throughout the year [46][47] Question: Long-term profitability of the infant formula business - The goal is to return to historical profit levels, with an ambition to achieve around $140 million in operating income [48][49] Question: Rollout plans for Opill - Opill is set for a nationwide rollout with strong retail and online activation plans, expected to generate significant initial revenue [50][51] Question: Confidence in resolving nutritional issues - Management expressed confidence in the remediation efforts, citing previous successful interventions in similar regulated industries [55][56] Question: Competitive landscape and share loss concerns - Management is working closely with retailers to minimize disruption and retain partnerships, emphasizing the importance of quality assurance [59][60] Question: 2025 targets and growth perspectives - Management plans to provide clearer growth perspectives during the Investor Day in the fall, focusing on executing current priorities [61][62]

Perrigo (PRGO) reported $1.16 billion in revenue for the quarter ended December 2023, representing a year-over-year increase of 0.2%. EPS of $0.86 for the same period compares to $0.75 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $1.19 billion, representing a surprise of -2.51%. The company delivered an EPS surprise of +3.61%, with the consensus EPS estimate being $0.83.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how ...

Adding HR photos ...